TOTAL VOLUME:
$95.2b
24H VOL:
$160,148,690
24H TRANSACTIONS:
920,787,070
OPEN INTEREST:
$1,984,144,418
798,286
Markets across
13,482
events
MATCHED EVENTS:
778
PLATFORM COVERAGE:
5
Polymarket:
45%
VS.
Kalshi:
55%
FDA approves MannKind's FUROSCIX ReadyFlow Autoinjector? Odds & Prediction Markets
90%
chance
Time left: 12d:23h:25m
FDA approves MannKind's FUROSCIX ReadyFlow Autoinjector?
$
$20
$50
$100
$500
Description
As of market creation, the FDA's expected decision date for the specified application is July 26, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for MannKind's FUROSCIX ReadyFlow Autoinjector as a treatment for edema in adults with chronic heart failure or chronic kidney disease by August 9, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Polymarket
As of market creation, the FDA's expected decision date for the specified application is July 26, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for MannKind's FUROSCIX ReadyFlow Autoinjector as a treatment for edema in adults with chronic heart failure or chronic kidney disease by August 9, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs The following do not constitute qualifying approvals: Approvable letters that require additional actions before approval Tentative approvals pending patent or exclusivity expiration FDA requests for additional information or studies Extension of Prescription Drug User Fee Amendments dates Approval for compassionate use or expanded access programs only Approval only for export or for use outside the United States Emergency Use Authorization (EUA) without full approval Complete Response Letters (CRLs) indicating the application cannot be approved in its current form This market will immediately resolve to "No" if the FDA issues a Complete Response Letter (CRL) or explicitly declines to approve the application. If the drug sponsor withdraws the application before the end of the specified period, the market will resolve to "No" immediately. If the listed drug is approved before the end of the specified period, the market will resolve to "Yes," regardless of potential Advisory Committee votes against approval or later withdrawal of approval. Conditional approvals may include post-marketing requirements or commitments and still qualify. The primary resolution source will be official information from the FDA; however, a consensus of credible reporting will also be used.
Frequently asked questions
Prediction market odds often diverge from traditional analyst forecasts because they incorporate real-money incentives and continuous price discovery. While pharmaceutical analysts may issue periodic reports on MannKind's regulatory prospects, this market aggregates the distributed knowledge of traders who profit or lose based on accuracy. Comparing the current odds to recent analyst commentary or FDA guidance on similar autoinjector submissions can reveal whether the market is pricing in optimism or caution relative to expert consensus.
On Polymarket, traders set prices by buying and selling binary outcome shares, with the current price reflecting the probability of FDA approval. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. The market operates as an automated market maker, meaning prices adjust dynamically based on order flow and liquidity. Higher prices indicate stronger trader confidence in approval, while lower prices suggest skepticism. Each share settles to either $1 or $0 upon resolution, making the price directly interpretable as an implied probability.
This market resolves around Jul 26, 2026, with the outcome confirmed once the event is verifiable from credible public reporting. Resolution hinges on whether the FDA formally approves MannKind's FUROSCIX ReadyFlow Autoinjector by that date. Official FDA announcements, regulatory filings, or credible news coverage documenting approval status will determine the final settlement. Traders should monitor FDA communications and MannKind investor updates as the deadline approaches.
Key catalysts include FDA advisory committee meetings, clinical trial data releases, or regulatory feedback letters from the agency. Announcements regarding manufacturing readiness, supply chain updates, or competitive approvals in the autoinjector space could also shift sentiment. Broader FDA policy changes affecting injectable drug approvals, or statements from MannKind leadership about regulatory timelines, may trigger significant price movement. Traders should track FDA meeting calendars and company earnings calls for material developments.
Follow the signals, not the noise
Get insights on market conviction, notable shifts, and what the data is quietly signaling.